B. Riley began coverage on shares of Zynex (OTCMKTS:ZYXI) in a research report released on Wednesday, The Fly reports. The brokerage issued a buy rating and a $7.00 price objective on the stock.
ZYXI has been the topic of a number of other research reports. Zacks Investment Research lowered Zynex from a hold rating to a sell rating in a report on Friday, August 10th. ValuEngine lowered Zynex from a hold rating to a sell rating in a report on Friday, August 3rd.
Shares of OTCMKTS ZYXI opened at $3.22 on Wednesday. The stock has a market cap of $99.17 million, a PE ratio of 14.64 and a beta of 0.78. Zynex has a 52 week low of $1.10 and a 52 week high of $5.50.
Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.01. The business had revenue of $7.57 million for the quarter, compared to analyst estimates of $7.75 million. Zynex had a return on equity of 205.15% and a net margin of 33.49%. Analysts expect that Zynex will post 0.28 earnings per share for the current year.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Read More: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.